NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

Lobbying for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$340,000.00

What this organization spent lobbying with its own staff. Reported using C: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Virginia

Official filing document

Government bodies contacted 12

Centers For Medicare and Medicaid Services (CMS)
Defense, Dept of (DOD)
Drug Enforcement Administration (DEA)
Federal Trade Commission (FTC)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Internal Revenue Service (IRS)
Justice, Dept of (DOJ)
SENATE
Treasury, Dept of
U.S. Customs & Border Protection
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 11

S 891
Bipartisan Health Care Act
S 882
Patients Before Middlemen Act
S 927
Protecting Pharmacies in Medicaid Act
HR 2428
Wildfire Homeowner Relief Act
HR 2214
DRUG Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
SCONRES 7
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…
S 587
Death Tax Repeal Act of 2025
S 526
Pharmacy Benefit Manager Transparency Act of 2025
S 527
Prescription Pricing for the People Act of 2025

Lobbying activity 10

Alcohol and Drug Abuse

Controlled Substances Prescribing & Dispensing; Comments to DOJ & DEA on "Ensuring Lawful Governance and Implementing the Presidents 'Department of Government Efficiency' Deregulatory Initiative"; Comments to DEA on "Special Registrations for Telemedicine and Limited State Telemedicine Registrations [Docket No. DEA-407]"

Medicare/Medicaid

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S. 927, the Protecting Pharmacies in Medicaid Act; the Equitable Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)'

Pharmacy

H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;

Taxation/Internal Revenue Code

S.587/1301, The Death Tax Repeal Act;

Labor Issues/Antitrust/Workplace

S.526, the Pharmacy Benefit Manager Transparency Act of 2025; S.527, the Prescription Pricing for the People Act of 2025;

Defense

TRICARE Pharmacy Network Oversight & Changes;

Budget/Appropriations

H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;

Telecommunications

Comments to HHS on "HIPAA Security Rule To Strengthen the Cybersecurity of Electronic Protected Health Information [HHS-OCR-0945-AA22]";

Trade (domestic/foreign)

Comments to CBP on "June 14, 2024, Internal Advice Letter H283420";

Small Business

Comments to the White House on the Corporate Transparency Act implementations (NDAA; P.L.116-283);

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.